Cantor Fitzgerald analyst Eliana Merle reiterated a Buy rating on AnaptysBio Inc (ANAB) today and set a price target of $140. The company’s shares closed on Friday at $63.74, close to its 52-week low of $54.26.
Merle commented:
“. We reiterate our OW and $140 TP. We hosted a to discuss the landscape for biologics in severe asthma. The physician believes IL-33 is a relevant and promising novel target for asthma, both for patients with type 2 and non-type 2 disease. With key data coming for ANAB’s IL-33 etokimab in 2H19 in atopic dermatitis and nasal polyps, we see significant upside (100-150%+) for the stock heading into 2H19 from IL-33 de- risking alone. Our recent atopic dermatitis KOL call (note) and checks at the AAAAI meeting (note) have also been supportive of etokimab’s potential. ANAB is a top pick heading into key 2H19 readouts for both the IL-33 and the IL-36R.”
According to TipRanks.com, Merle is a 1-star analyst with an average return of -5.2% and a 22.7% success rate. Merle covers the Healthcare sector, focusing on stocks such as Aerpio Pharmaceuticals Inc, CymaBay Therapeutics, and Galapagos NV.
AnaptysBio Inc has an analyst consensus of Strong Buy, with a price target consensus of $130, representing a 104.0% upside. In a report issued on March 4, H.C. Wainwright also reiterated a Buy rating on the stock with a $126 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $122.48 and a one-year low of $54.26. Currently, AnaptysBio Inc has an average volume of 269K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies.
